Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices traded up today The three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 6.62 points (0.0%) at 17,862 as of Wednesday, Feb. 11, 2015, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,395 issues advancing vs. 1,696 declining with 137 unchanged.

The Health Care sector as a whole closed the day up 0.1% versus the S&P 500, which was unchanged. Top gainers within the Health Care sector included VirtualScopics ( VSCP), up 2.6%, Reliv' International ( RELV), up 3.4%, Huttig Building Products ( HBP), up 2.5%, Great Basin Scientific ( GBSN), up 2.9% and Semler Scientific ( SMLR), up 3.9%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today:

Semler Scientific ( SMLR) is one of the companies that pushed the Health Care sector higher today. Semler Scientific was up $0.16 (3.9%) to $4.25 on light volume. Throughout the day, 5,547 shares of Semler Scientific exchanged hands as compared to its average daily volume of 12,900 shares. The stock ranged in a price between $4.00-$4.40 after having opened the day at $4.00 as compared to the previous trading day's close of $4.09.

Semler Scientific has a market cap of $19.5 million and is part of the health services industry. Shares are up 108.7% year-to-date as of the close of trading on Tuesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Reliv' International ( RELV) was up $0.04 (3.4%) to $1.21 on light volume. Throughout the day, 8,111 shares of Reliv' International exchanged hands as compared to its average daily volume of 14,100 shares. The stock ranged in a price between $1.18-$1.21 after having opened the day at $1.18 as compared to the previous trading day's close of $1.17.

Reliv' International, Inc. develops, manufactures, and markets nutritional supplements that promote basic nutrition, weight loss, athletic performance, digestive health, women's health, anti-aging, and healthy energy. Reliv' International has a market cap of $14.7 million and is part of the health services industry. Shares are unchanged year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Reliv' International a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Reliv' International as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, feeble growth in the company's earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on RELV go as follows:

  • The gross profit margin for RELIV INTERNATIONAL INC is currently very high, coming in at 80.94%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, RELV's net profit margin of 1.15% significantly trails the industry average.
  • Although RELV's debt-to-equity ratio of 0.27 is very low, it is currently higher than that of the industry average. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.87 is somewhat weak and could be cause for future problems.
  • RELV, with its decline in revenue, underperformed when compared the industry average of 10.2%. Since the same quarter one year prior, revenues fell by 13.4%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • RELIV INTERNATIONAL INC's earnings per share declined by 50.0% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, RELIV INTERNATIONAL INC reported lower earnings of $0.06 versus $0.10 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Personal Products industry. The net income has significantly decreased by 43.3% when compared to the same quarter one year ago, falling from $0.29 million to $0.17 million.

You can view the full analysis from the report here: Reliv' International Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

VirtualScopics ( VSCP) was another company that pushed the Health Care sector higher today. VirtualScopics was up $0.08 (2.6%) to $3.18 on heavy volume. Throughout the day, 23,371 shares of VirtualScopics exchanged hands as compared to its average daily volume of 4,300 shares. The stock ranged in a price between $2.85-$3.49 after having opened the day at $2.92 as compared to the previous trading day's close of $3.10.

VirtualScopics, Inc. provides imaging solutions for the pharmaceutical, biotechnology, and medical device industries. VirtualScopics has a market cap of $8.6 million and is part of the health services industry. Shares are down 2.2% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates VirtualScopics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates VirtualScopics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on VSCP go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 27.3% when compared to the same quarter one year ago, falling from -$0.75 million to -$0.96 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, VIRTUALSCOPICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for VIRTUALSCOPICS INC is currently lower than what is desirable, coming in at 33.86%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -34.87% is significantly below that of the industry average.
  • Net operating cash flow has significantly decreased to -$0.42 million or 200.00% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • Reflecting the weaknesses we have cited, including the decline in the company's earnings per share, VSCP has underperformed the S&P 500 Index, declining 13.20% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

You can view the full analysis from the report here: VirtualScopics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.